

# Randomised double-blind placebo controlled trial of effect of Ginkgo biloba on cognitive function in mild-moderate dementia

<b>Submission date</b> 02/08/2002	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 02/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 11/07/2007	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr James Warner

**Contact details**  
Senior Lecturer  
Imperial College School of Medicine  
St Charles Hospital  
Exmoor Street  
London  
United Kingdom  
W10 6DZ  
+44 (0)20 8962 4101  
j.warner@ic.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

## Secondary identifying numbers

QRD/2001/01/07

# Study information

## Scientific Title

## Acronym

DIGGER

## Study objectives

Null Hypothesis: high purity ginkgo biloba extract does not improve cognition quality of life or carer burden in individuals with mild-moderate dementia. NB: this study will also assess the magnitude of the Hawthorne effect in dementia trials.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Received from Multi-centre Research Ethics Committee (ref: MREC/02/6/35).

## Study design

Randomised double-blind placebo controlled parallel group study

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

GP practice

## Study type(s)

Not Specified

## Participant information sheet

## Health condition(s) or problem(s) studied

Dementia

## Interventions

1. The active intervention will be concentrated, standardised Ginkgo biloba extract (25% active Ginkgo-flavoneglycosides), prepared according to accepted guidelines in a 60 mg tablet (EGB-761, Schwabe)
2. The placebo will be 60 mg of inert lactose with 2 mg quinine sulphate

## Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Ginkgo extract

**Primary outcome measure**

Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) at six months.

**Secondary outcome measures**

All at six months:

1. Participant: Quality of Life scale in Alzheimers disease (QoL-AD), Neuropsychiatric Inventory questionnaire (NPI), Geriatric Evaluation by Relative's Rating Instrument (GERRI), adverse events
2. Carer: European Quality of life questionnaire (EQ-5D), Zarit caregiver Burden Interview (ZBI)

**Overall study start date**

01/04/2003

**Completion date**

31/12/2005

**Eligibility****Key inclusion criteria**

1. Aged 55 years and over
2. Clinician's diagnosis of dementia
3. Presence of a carer
4. Consent of patient and carer
5. Sufficient command of English to complete questionnaires
6. Mini Mental State Examination (MMSE-23) score of 15 - 24

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Both

**Target number of participants**

Target: 200

**Key exclusion criteria**

1. Commencement of acetylcholinesterase therapy within two months of recruitment
2. Current anticoagulant therapy
3. Abnormal clotting profile

**Date of first enrolment**

01/04/2003

**Date of final enrolment**

31/12/2005

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Senior Lecturer**

London

United Kingdom

W10 6DZ

## **Sponsor information**

**Organisation**

Alzheimer's Society (UK)

**Sponsor details**

Gordon House

10 Greencoat Place

London

United Kingdom

SW1P 1PH

+44 (0)20 7306 0606

enquiries@alzheimers.org.uk

**Sponsor type**

Charity

**ROR**

<https://ror.org/0472gwq90>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Alzheimer's Society (UK)

**Alternative Name(s)**

alzheimerssoc

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Associations and societies (private and public)

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	03/07/2007		Yes	No